2 points .. actually 3
anyone *here* think the
2 points .. actually 3
anyone *here* think the *trading* on IPIX is *normal* .. especially since the last
52 week low reset of 63c on 5.10.17 and particularly after the events of mgmt's
surprise almost one month later on 6.8.17/6.9.17???
the short %s are done on the *float* (which are freely trading shares) not the I/O
(issued/outstanding which includes restricted shares not traded) .. which is why
it's worth noting the aggregate noted over months/years .. and why 2+ years ago
b4 the *execution* by the abusive shorts .. IPIX held an aggregate short of
approx 1.2M - 1.3M .. that aggregate (btw this is what is reported by SROs
which are self reporting entities) .. was *reduced* after all those *gyrations*
(Mako/CA/yada yada) to approx 800M~ which it held until the events of earlier
this year .. when SROs' once again had to *report* 1.2M ~
anyone think that is normal?
here are IPIX's *volume* avgs ..
IPIX Volume 0
Volume (10 day Average) 181,659
Volume (90 day Average) 205,174
when an entity is upside down (this is never retail)
you see a few *tells* .. first is volume avgs .. NR can no longer maintain the
illusion of *volume* for crews' embedded to whine about ________ insert seller
the tape of trades when viewed in total (and some times over 2 or 3 days) is
equally telling .. but mostly anyone who actually buys or sells can match their
respective time stamps to see how *handled* .. is the bid filled in total/split filled/mirrored 1x .. 2x .. 3x?
every appearance for weeks now is being given of wanting to *reset* the 52 week low yet again ..
in NRs' (non retails) cycles of money .. this is SOP (standard operating procedure)
they like to work cycles 1 to 3x per year *imo* ... however when upside down
as they are on IPIX (again imo) the arrow can only go one way .. *down* hence
the relentless compression .. because let's be crystal clear here .. *most* retail
can have their emotions' worked when they see a PPS CONsistently compressed
make no mistake of what is being done and why .. they need actual *shares*
imo IPIX (unlike some other OTC targets NR is also upside down on) has always
had liquidity .. but as many can see .. it's been drying up since NRs' epic fail last May
4kids
6
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Community Need Drives Event Extension October in Jonesboro just got a bit more hopeful for breast cancer survivors—it's not just about awareness anymore; it's about action. The United Breast Cancer Foundation (UBCF) has decided to extend its popular Pink Bag free shopping event through October 30th. What spurred this decision? Well, the overwhelming community demand,...
Continue Reading
Mapping the Complex Maze of MicroRNA on Circular RNAs Pusan National University's brainiacs have cooked up something spicy for the bioinformatics world. They've developed this snazzy AI tool, circMAC, to unravel microRNA binding mysteries on circular RNAs. 'Why’s this such a big deal?' you ask. Well, these loop-shaped critters, circRNAs, play a backstage role in gene...
Continue Reading
A New Era for Podium When the brass at Podium made a gamble on AI, they didn't just try squeezing it into their old business model. Oh no, they launched what feels like a startup within their existing empire—no half-measures, just full-throttle ambition. Fast forward two and a half years, and they've racked up over $150 million in annual recurring revenue from these...
Continue Reading
Rethinking How We Evaluate Drug Abuse Potential Sometimes, the finance world gets a peek into something that ain't just about the numbers on a screen, something with real stakes beyond the bulls and bears. Labcorp's just thrown its hat in with the FDA and Charles River Laboratories in a collaboration that goes beyond just lining pockets. They're setting up to dissect how...
Continue Reading
Vertice Dives Deeper into the Procurement Game Grab a coffee and let's talk some procurement—one of the least sexy, yet utterly essential parts of any operation. Vertice's latest announcement is anything but mundane. They're spiraling deeper into the procurement universe with their new Procure-to-Pay (P2P) capability, a bold expansion from their Intake-to-Procure (I2P)...
Continue Reading
AI Investments Without Returns: The Current Scenario Well, wouldn't you know it? Enterprises have sunk a fortune into AI, and they're wagging their fingers once more at the mounting bills with little to show for it. Play the investment game long enough, and it seems you'll find the numbers don't always rub together and make sparks. This familiar tune of over-budget...
Continue Reading
Puerto Rico Welcomes College Football with Open Arms Imagine kicking towards the goalposts while the ocean breeze kisses your face—yep, that's what's happening in Puerto Rico this December. TransPerfect, a heavyweight in language and tech solutions, is rolling out the red carpet for the inaugural TransPerfect San Juan Bowl, and it’s not just a game. It’s a bold step...
Continue Reading
A Mighty Move in Manufacturing Carrier Global Corporation's recent muscle-flexing is something rarer than a golden goose in today's market—a $600 million thrust into beefing up U.S. manufacturing and engineering. You can't help but wonder if this is overzealous optimism or a meticulously calculated power play. Clocks don't tick this loudly without good reason, of...
Continue Reading
Innventure's Murky Waters Just when you think you've seen it all, stuff like this reminds you nothing's safe in the market. The law folks at Stranch, Jennings & Garvey, PLLC are sniffing around Innventure, Inc. (NASDAQ: INV) like bloodhounds to see if there's been some hoodwinking going on. We're talking questions about funny business with a data center deal between...
Continue Reading
The Satellite Race Heats Up: Xona's Ambitious Leap Hold onto your hats, folks, because Xona's making headlines with a $250 million infusion. This ain't just pocket change—it's part of a rocket-fueled mission to upend the GPS landscape. Imagine a world where GPS is 100 times stronger. That's the pitch, and folks, it's got the market buzzing. Valuation Rocketing: Investor...
Continue Reading
Top 5 Most Recently Viewed Articles
osapiens Secures Major Funding Round osapiens, a leading firm in enterprise software dedicated to encouraging sustainable growth, has recently announced a significant financial milestone. The company has secured an impressive US$ 100 million in a Series C funding round, spearheaded by Decarbonization Partners, a collaboration between BlackRock and Temasek. This newfound...
Continue Reading
Microsoft and Thrive Global Join Forces for Employee Wellbeing Microsoft has embarked on an inspiring journey by partnering with Thrive Global, a company that specializes in behavior change strategies aimed at enhancing overall wellbeing. This collaboration aims to integrate a range of wellbeing resources seamlessly into the daily operations of Microsoft Teams, making it...
Continue Reading
Coventry First LLC Files Motion to Dismiss Lawsuit Coventry First LLC, along with Co-Founder and Executive Chairman Alan H. Buerger, is taking a decisive stand against the lawsuit filed by Abacus Global Management, Inc. This move comes in response to a claim that Coventry believes lacks merit, particularly in light of recent industry changes. Key Developments Around the...
Continue Reading
AbbVie Declares Quarterly Dividend The board of directors at AbbVie Inc. (NYSE: ABBV) has announced a quarterly cash dividend of $1.55 per share. This decision reflects the company's ongoing commitment to providing value to its shareholders through dependable and substantial dividend distributions. Details and Timeline for the Dividend The announced dividend will be paid...
Continue Reading
GitLab's Growing Demand for 'Ultimate' GitLab Inc (NASDAQ: GTLB) has recently experienced a notable uptick in the adoption of its 'Ultimate' offering, according to industry expert insights. The stock saw a boost when analyst Mike Cikos from Needham raised its rating from Hold to Buy, setting a price target of $70. This optimistic outlook is backed by GitLab's continued...
Continue Reading